BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

The Day In Review: Pfizer Inc. (PFE) Anti-Smoking Drug Chantix Gets Approved


5/11/2006 6:26:32 PM

May 11, 2006 – Pfizer received FDA approval for its anti-smoking drug, Chantix; Neurogen's insomnia drug, NG2-73, was effective in a Phase II study for insomnia; Gilead sold off a poor-selling cancer drug to Diatos for $4.7 million plus royalties; Gleevac from Novartis may inhibit bone formation, according to a small study; Prana Biotech will move its Alzheimer’s drug into Phase II tests; Targeted Genetics executed a 1-for-10 reverse split and changed its symbol; Biovest won approval to market AutovaxID, a device that produces cell-derived products for personalized medicine applications; and Alfacell presented new data on Onconase as a treatment for non-small cell lung cancer. The Centient Biotech 200™ was off by 32 points at 3704.72, a loss of .86%. More details...

Read at ChinaBio Today


   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->